
    
      This study will be performed to explore the antiviral activity, clinical outcomes, safety,
      tolerability, and pharmacokinetics of JNJ-53718678 in adult participants infected with RSV.
      The study will include both participants who are otherwise healthy (ie, without underlying
      condition) or who have comorbid conditions (eg, asthma, chronic obstructive pulmonary disease
      (COPD), cardiovascular disease, other chronic diseases), with the exception of
      immunocompromised participants, presenting for medical care but not requiring
      hospitalization. The study will include a screening period (Day -1 to Day 1), a treatment
      Period (Day 1 to Day 8), and a follow-up period (Day 9 to Day 28). Safety evaluations will
      include adverse events, laboratory tests, electrocardiogram, vital signs, physical
      examination, and specific toxicities.
    
  